Previous 10 | Next 10 |
Viveve 2.0 System now available throughout North America, Asia, and over 30 European countries ENGLEWOOD, CO / ACCESSWIRE / April 16, 2020 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced it has received regulatory cl...
Viveve Medical (NASDAQ: VIVE ) has resubmitted its Investigational Device Exemption (IDE) to the FDA for approval to begin a stress urinary incontinence (SUI) trial now entitled, PURSUIT - Prospective U.S. Radiofrequency SUI Trial. More news on: Viveve Medical, Inc., Healthcare stoc...
Proposed pivotal trial reinforces the company's strategic pursuit of label expansion for Cryogen-cooled, Monopolar Radiofrequency (CMRF) technology in SUI indication ENGLEWOOD, CO / ACCESSWIRE / April 15, 2020 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused o...
ENGLEWOOD, CO / ACCESSWIRE / April 9, 2020 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced topline results from the VIVEVE II clinical trial. VIVEVE II is a multicenter, randomized, double-blinded, sham-controlled study t...
Viveve 2.0 cryogen-cool monopolar radiofrequency technology and consumable treatment tips are now available in the U.S., China, Hong Kong, South Korea, Taiwan and more than 30 European countries ENGLEWOOD, CO / ACCESSWIRE / March 26, 2020 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical ...
Viveve Medical, Inc. (VIVE) Q4 2019 Earnings Conference Call March 19, 2020 17:00 ET Company Participants Jeannie Swindle - Senior Director, Corporate Communications Scott Durbin - Director & CEO Conference Call Participants Presentation Operator Good day, and wel...
Viveve Medical (NASDAQ: VIVE ): FY GAAP EPS of -$34.39. More news on: Viveve Medical, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Company completes successful U.S. commercial transition from traditional capital sales model to recurring revenue rental model Landmark pivotal sexual function trial (VIVEVE II) completed with data readout scheduled for April SUI clinical development program with short-term feasib...
Unblinded top-line results of the 12-month U.S. study anticipated in April If positive, results may support a 2020 marketing application for an expanded U.S. indication for improvement of sexual function in women ENGLEWOOD, CO / ACCESSWIRE / March 12, 2020 / Viveve Medical, ...
ENGLEWOOD, CO / ACCESSWIRE / March 6, 2020 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will provide a corporate update and report its year-end 2019 financial results after the close of the U.S. financial marke...
News, Short Squeeze, Breakout and More Instantly...
Novonix Limited (NVNXF) is expected to report for quarter end 2023-12-31 MedAvail Holdings Inc. (MDVL) is expected to report for Q3 2023 Nobility Homes, Inc. (NOBH) is expected to report for quarter end 2023-10-31 Walgreens Boots Alliance Inc. (WBA) is expected to report $0.66 for Q1 ...
Disco Corporation ADR (DSCSY) is expected to report for Q2 2024 Sonic Foundry Inc. (SOFO) is expected to report for quarter end 2023-09-30 Sono Group N.V. (SEVCQ) is expected to report for quarter end 2023-09-30 Minim Inc (MINM) is expected to report for Q3 2023 Enel Spa ADR (ENLA...
Enel Spa ADR (ENLAY) is expected to report for Q3 2023 LEG Immobilien SE Registered Shares (LEGIF) is expected to report for Q3 2023 G. Willi-Food International Ltd. (WILC) is expected to report for Q3 2023 Worthington Steel Inc. (WS) is expected to report $0.15 for Q2 2024 Sonic ...